Kevin S. Boyle Sr. - 30 Aug 2021 Form 4 Insider Report for ZIOPHARM ONCOLOGY INC (TCRT)

Role
Chief Executive Officer, Director
Signature
/s/ Timothy Cunningham, Attorney-in-Fact
Issuer symbol
TCRT
Transactions as of
30 Aug 2021
Net transactions value
$0
Form type
4
Filing time
31 Aug 2021, 16:42:26 UTC
Next filing
17 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRT Common Stock Award $0 +875,000 $0.000000 875,000 30 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRT Employee Stock Option (right to buy) Award $0 +2,625,000 $0.000000 2,625,000 30 Aug 2021 Common Stock 2,625,000 $1.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares vest on each of August 30, 2022, August 30, 2023, August 30, 2024 and August 30, 2025, subject to the Reporting Person's continued service through each such date.
F2 One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three month after 8/30/2021, subject to the Reporting Person's continued service through each such date.